BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25531331)

  • 1. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.
    Cui J; Yang Y; Li H; Leng Y; Qian K; Huang Q; Zhang C; Lu Z; Chen J; Sun T; Wu R; Sun Y; Song H; Wei X; Jing P; Yang X; Zhang C
    Oncogene; 2015 Jul; 34(30):3895-907. PubMed ID: 25531331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
    PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
    Zheng L; Meng X; Li X; Zhang Y; Li C; Xiang C; Xing Y; Xia Y; Xi T
    FASEB J; 2018 Feb; 32(2):588-600. PubMed ID: 28939591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
    Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
    Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 6. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.
    Zheng XQ; Guo JP; Yang H; Kanai M; He LL; Li YY; Koomen JM; Minton S; Gao M; Ren XB; Coppola D; Cheng JQ
    Oncogene; 2014 Oct; 33(42):4985-96. PubMed ID: 24166501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
    Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
    J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Estrogen-Regulated
    Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
    Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells.
    Lee YM; Lee JY; Ho CC; Hong QS; Yu SL; Tzeng CR; Yang PC; Chen HW
    Breast Cancer Res; 2011; 13(6):R116. PubMed ID: 22113133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
    Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
    Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J; Lu M; Jin J; Lu X; Xu T; Jin S
    Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway.
    Liu J; Li Y
    Biochem Biophys Res Commun; 2015 Nov; 467(2):242-7. PubMed ID: 26436206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
    Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J
    Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
    Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
    Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.
    Wei Y; Lai X; Yu S; Chen S; Ma Y; Zhang Y; Li H; Zhu X; Yao L; Zhang J
    Breast Cancer Res Treat; 2014 Sep; 147(2):423-31. PubMed ID: 25007959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
    Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
    Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.